N
NewLimit
Epigenetic reprogramming medicines to treat age-related disease
About NewLimit
NewLimit is a pioneering biotech startup focused on developing medicines that aim to extend human healthspan by reprogramming the epigenome of aging cells. The company operates in the cutting-edge field of epigenetic reprogramming, which involves altering the chemical modifications on DNA and histone proteins to restore youthful function in old cells. This approach targets diseases associated with aging, with initial programs concentrating on rejuvenating the immune system and liver.
Read full description
NewLimit's business model revolves around leveraging advanced technologies such as single-cell genomics, machine learning, and high-throughput functional assays. These technologies help the company identify the epigenetic markers of aging and develop interventions to reverse these changes. By doing so, NewLimit aims to create a new class of medicines that can significantly extend the period of life spent in good health.
The company primarily serves the healthcare market, targeting patients suffering from age-related diseases and conditions. Its clients include pharmaceutical companies, healthcare providers, and potentially, individual consumers seeking anti-aging treatments. NewLimit generates revenue through the development and commercialization of its proprietary medicines, as well as through partnerships and collaborations with other entities in the biotech and pharmaceutical industries.
In summary, NewLimit is at the forefront of a revolutionary approach to healthcare, aiming to extend human healthspan by reprogramming the biology of aging cells. The company combines state-of-the-art technologies to discover and develop new medicines that could transform the way we age.
At a glance
- Founded
- 2021
- Headquarters
- South San Francisco, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning NewLimit.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A16 investors entered at this stage
Kleiner Perkins
Founders Fund
Dimension
Fred Ehrsam
Garry Tan
Eric Schmidt
Elad Gil
Joe Lonsdale
Patrick Collison
Nat Friedman
Daniel Gross
Valor Equity Partners
Joshua Kushner
John Collison
Human Capital
Khosla Ventures
Series B and later10 investors entered at this stage
Boost VC
Abstract Ventures
Eli Lilly
Brian Armstrong
Section 32
Duke Management Company
Greenoaks Capital Partners
Lilly Ventures
Quiet Capital
Thrive Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about NewLimit on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NewLimit on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.